Safety study of Luspatercept for MDS or thalassemia in Korea
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have myelodysplastic syndrome or beta-thalassemia.
- Your doctor plans to prescribe Luspatercept as it is approved for use in Korea.
- You are willing to sign a consent form to join the study.
- You do not have any medical condition that would make Luspatercept unsafe for you (as listed in the Korean product information).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
This trial tests a drug called luspatercept (Reblozyl) as the first treatment for people with a bone marrow disorder that causes low blood counts and requires regular blood transfusions. The drug may help reduce the need for transfusions by improving red blood cell production.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.